COVID-19–induced olfactory loss - 05/04/23

Key words : Hyposmia, anosmia, smell, corona virus, SARS
El texto completo de este artículo está disponible en PDF.
Esquema
Disclosure of potential conflict of interest: In the past 5 years, M. Laudien has engaged in cooperation with Olympus Deutschland GmbH, Olympus Europa SE and Co KG, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Brainlab Sales GmbH, GlaxoSmithKline GmbH and Co KG, and the John Grube Foundation. B. A. Stuck has received research grants, reimbursement of travel expenses, and speaking fees from GlaxoSmithKlinie GmbH and Co KG, Merck, and Sanofi; in addition, his department has received financial support for meetings or symposia from Bristol-Myers Squibb, Merck, Neuwirth Medical Products, ALK, Sanofi, Pohl-Boskamp, MSD, and Takeda. In the past 5 years, T. Hummel has engaged in cooperation with Sony (Stuttgart, Germany), Smell and Taste Lab (Geneva, Switzerland), Takasago (Paris, France), aspUraclip (Berlin, Germany), Baia Foods (Madrid, Spain), Bayer (Berlin, Germany), Procter and Gamble (London, United Kingdom) Burghart (Wedel, Germany), and Primavera (Oy-Mittelberg, Germany). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 4
P. 895-897 - avril 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.